Autoimmune haemolytic anaemia (AIHA), immune thrombocytopenia (ITP) and autoimmune neutropenia (AIN) are well-recognised complications of allogeneic stem cell transplantation (SCT), but have previously only been reported in the context of myeloablative conditioning regimens. Management of AIHA, ITP or AIN occurring after allogeneic SCT is unsatisfactory since they frequently prove refractory to conventional therapies including splenectomy. As a consequence, autoimmune cytopenias occurring after allogeneic SCT are associated with substantial morbidity and mortality. We report four patients who developed AIHA or ITP after allogeneic transplantation -three of which occurred after a reducedintensity conditioning (RIC) regimen. All patients demonstrated a complete response to Rituximab, having failed to respond to conventional treatment including high-dose prednisolone and intravenous immunoglobulin (IVIg). We conclude that Rituximab can be a valuable agent in the management of autoimmune cytopenias occurring after allogeneic SCT and that autoimmune cytopenias may be a hitherto unrecognised complication of RIC regimens.
intensity allogeneic stem cell transplant Autoimmune haemolytic anaemia (AIHA) and immune thrombocytopenia (ITP) are well-recognised complications of allogeneic stem cell transplantation (SCT). The management of such patients can be complex since they often prove refractory to conventional treatments including splenectomy. We report four patients who presented with autoimmune cytopenia after allogeneic SCT. Although there was no response to treatment with corticosteroids or immunoglobulin (IVIg), a durable response to Rituximab was documented in all patients.
Patients (Table 1) and results

Patient 1:
A 32-year-old male with refractory Hodgkin's disease stage underwent a volunteer unrelated donor (VUD) transplant using a myeloablative conditioning regimen consisting of total body irradiation 1440 cGy in eight fractions, cyclophosphamide and alemtuzumab. He received cyclosporine/methotrexate as graft-versus-host disease (GVHD) prophylaxis. At 69 days post transplant rash, diarrhoea and severe thrombocytopenia (Hb 8.6 g/dl, WBC 4.8 Â 10 9 /l, platelets 5 Â 10 9 /l) developed. A bone marrow aspirate was normocellular and contained abundant megakaryocytes. A diagnosis of AITP was made. Chimerism studies revealed mixed donor chimerism. There was no increase in platelet count after treatment with prednisolone and IVIg and Rituximab 375 mg/m 2 (weekly Â 4) was commenced. The platelet count rapidly improved rising to 210 Â 10 9 /l after the completion of Rituximab therapy. The platelet count has remained in the normal range for 14 months.
Patient 2: A 41-year-old woman with relapsed follicular lymphoma underwent a sibling allograft using a BEAM (carmustine, etoposide, cytarabine, melphelan) and alemtuzumab RIC regimen. She received cyclosporine/methotrexate for GVHD prophylaxis. At 9 months post transplant, she became jaundiced (bilirubin 67 mmol/l) and was found to be anaemic (Hb 7.3 g/dl) and thrombocytopenic (34 Â 10 9 /l). The peripheral blood film showed reticulocytosis, polychromasia and spherocytosis, but no red cell fragmentation. The direct Coomb's test was positive. A bone marrow aspirate demonstrated erythroid hypercellularity and a marked increase in megakaryocyte numbers. There was no evidence of disease recurrence. Chimerism studies showed 100% donor chimerism. A diagnosis of AIHA and ITP was made. She was treated with methylprednisolone and IVIg with complete resolution of haemolysis, but only a modest increase in her platelet count. After 2 months, she developed recurrent haemolysis and thrombocytopenia, which proved refractory to prednisolone and IVIg. She underwent splenectomy with complete resolution of her immune haemolysis but no improvement in her platelet count. In view of refractory thrombocytopenia, she was treated with Rituximab (375 mg/m 2 weekly Â 4). Within 1 week, her platelet count had risen to normal and has remained within normal limits for more than 15 months. Repeat chimerism studies demonstrated 100% donor chimerism. There has been no evidence of recurrent haemolysis for the past 19 months.
Discussion
AITP and AIHA are well-recognised complications of allogeneic SCT using a myeloablative conditioning regimen. [1] [2] [3] [4] [5] The frequency of AIHA has previously been reported to be increased in patients receiving allografts in which T cells have been depleted from the donor stem cell inoculum. Cwynarski et al 4 reported 15% of patients undergoing transplantation using a myeloablative conditioning regimen incorporating alemtuzumab developed AIHA, which appeared to be associated with the presence of mixed T cell chimerism and responded to donor lymphocyte infusion (DLI). This has led to the proposal that T-cell depletion may contribute to dysregulated B-cell function post transplant, resulting in autoantibody formation. The use of RIC regimens has been shown to decrease the toxicity of allogeneic SCT, permitting its extension to large numbers of patients in whom it was previously contraindicated. [6] [7] [8] [9] Incorporation of alemtuzumab into the preparative regimen results in a significant degree of T-cell depletion and decreases the risk of acute and chronic GVHD. There have been no previous reports of autoimmune cytopenias in patients conditioned using a RIC regimen. Given the increasing use of pre-transplant alemtuzumab in RIC regimens, it will be important to monitor the frequency of such complications in future.
Rituximab is a chimeric human:mouse monoclonal antibody which shows significant clinical activity in patients with non-Hodgkins lymphoma if administered alone or in combination with chemotherapy. Rituximab results in depletion of normal and malignant CD20-positive lymphocytes through binding of its Fab domain to the CD20 antigen on B lymphocytes. A number of mechanisms have been proposed for the activity of rituximab, including complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity and a direct proapoptotic effect. In addition to its activity in lymphoid malignancies, Rituximab has been shown to be an active agent in the treatment of autoimmune cytopenias refractory to conventional treatment, particularly chronic idiopathic thrombocytopenic purpura and AIHA. [10] [11] [12] In all, 40% of patients with refractory chronic ITP respond to Rituximab, with over half of these responses proving durable. Similarly encouraging responses have been reported in patients with AIHA refractory to steroids and splenectomy. Treatment of AIHA and AITP after allogeneic SCT is unsatisfactory and as a consequence is associated with substantial morbidity and mortality. In view of the limited response rates and significant toxicities associated with conventional therapies, alternative therapies need to be evaluated. All of the patients reported here with autoimmune cytopenias occurring after allogeneic SCT demonstrated a prompt and durable response to Rituximab, having failed conventional therapies including high-dose corticosteroids, IVIg and splenectomy. Rituximab has previously been reported to be of benefit in two patients with AIHA post allograft and one patient with profound thrombocytopenia complicating severe chronic GVHD. [13] [14] [15] The aetiology of thrombocytopenia occurring in patients with severe GVHD is complex and likely to differ from ITP, which commonly occurs in the absence of evidence of active GVHD. It will also be of interest to examine whether Rituximab is of benefit in patients with AIN occurring post transplant. 5 There are theoretical concerns that the profound B-cell depletion consequent upon Rituximab administration in the context of allogeneic SCT could compromise immune reconstitution further and be associated with unacceptable infectious complications. It is of note that there were no short or long-term infectious complications experienced by patients in this study. The mechanism by which Rituximab is of benefit in autoimmune cytopenias developing post allograft is unclear. It is likely to reflect B-cell depletion, but it is important to note that a small population of CD20-positive T cells is also depleted during Rituximab administration.
Although all patients reported in this series received in vivo alemtuzumab as a form of T cell depletion, we did not identify a consistent relationship between the chimerism status and the development of autoimmune cytopenias in contrast to previous reports. These data therefore support the use of Rituximab rather than DLI as the management of choice in patients with refractory cytopenias occurring after allogeneic SCT. They also demonstrate that it will be important to assess the incidence of autoimmune cytopenias in recipients of patients receiving RIC allografts, particularly those who receive alemtuzumab as a component of the preparative regimen.
